ProKidney and Social Capital Suvretta Holdings III plan to host a presentation April 28 at 8 a.m. ET on their proposed merger.
ProKidney is a Phase 3 clinical-stage cellular therapeutics company with Regenerative Medicine Advanced Therapy Designation that has the goal of delaying chronic kidney disease, preventing end-stage renal disease as well as the need for dialysis.
The analyst day will feature presentations from the ProKidney and SCS leadership teams, including Pablo Legorreta, ProKidney’s Chairman, Tim Bertram, CEO and Founder, Chamath Palihapitiya, founder and CEO of Social Capital and Chairman and CEO of SCS, and Kishen Mehta, Portfolio Manager of the Averill strategy at Suvretta Capital Management and Director and President of SCS.
A live webcast of the event will be available on the ProKidney and SCS websites at www.prokidney.com and www.socialcapitalsuvrettaholdings.com/dnac.
With an equity value of $2.64 billion, the deal announced in January is expected to deliver up to $825 million to ProKidney, including the contribution of up to $250 million of cash held in the SPAC’s trust, less any redemptions, and a fully committed PIPE of $575 million. Read more.
